Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis

Journal of Neurology

Volumn 251, Issue 11, 2004, Pages 1297-1303

  Tremlett, Helen ^a   Oger, Joel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adverse drug reactions; Aminotransferases; Beta interferon; Hepatic injury; Multiple sclerosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; BETA1A INTERFERON; BILIRUBIN; CARBAMAZEPINE; CIMETIDINE; FUROSEMIDE; GAMMA INTERFERON; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; INTERFERON BETA SERINE; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; SENNA EXTRACT; VALPROIC ACID;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; BIOCHEMISTRY; BODY MASS; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; EXERCISE; GENERAL PRACTICE; HUMAN; INCIDENCE; LABORATORY TEST; LIVER INJURY; LIVER TOXICITY; MORTALITY; MULTIPLE SCLEROSIS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX RATIO;

ASPARTATE AMINOTRANSFERASES; DRUG MONITORING; HUMANS; INTERFERON-BETA; LIVER DISEASES; LIVER FUNCTION TESTS; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS; SEX FACTORS;

EID: 12744269309     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0619-5     Document Type: Review

References (59)

1. Ferguson J, Sandrock A (2003) Important New Prescribing Information. http://www.fda.gov/medwatch/SAFET Y/2003/avonex_deardoc.pdf (Accessed 16 Dec 2003)
2. Gehshan A, Ruebig A, Salesse M (2003) Important new safety information: Hepatic injury associated with beta-interferon treatment for Multiple Sclerosis http://www.hc-sc.gc.ca/hpfb-dgpsa/ tpd-dpt/beta-interferon_hpc_e.pdf (Accessed 16 Dec 2003)
3. CDER-PHRMA-AASLD (2000) Drug-induced hepatotoxicity White Paper Postmarketing Considerations. http:www//fda.gov/cder/livertox/postmarket.pdf (Accessed 28 July 2003)
4. Lewis JA (1981) Post-marketing surveillance - how many patients? Trends Pharmacol Sci 2:93-94
5. Rawlins MD (1988) Spontaneous reporting of adverse drug reactions I: The data. Br J Clin Pharmacol 26:1-5
6. Zakim D, Boyer T (1996) Hepatology: A textbook of liver disease (London, Saunders)
7. th 2003)
8. Kaplan MM (2002) Alanine amino-transferase levels: what's normal? Ann Intern Med 137:49-51
9. Pratt DS, Kaplan MM (2000) Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 342:1266-1271
10. Kew M (2000) Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355:591-592
11. Dufour DR (2000) Laboratory guidelines for screening, diagnosis and monitoring of hepatic injury. Washington, D.C., USA: National Academy of Clinical Biochemistry
12. Minuk GY (1998) Canadian Association of Gastroenterology Practice Guidelines: Evaluation of abnormal liver enzyme tests. Can J Gastroenterol 12:417-421
13. Crispe I (1999) T lymphocytes in the Liver. Wiley-Liss, New York
14. Dobin NB, Switzer JL (1954) Liver function and other blood chemistry tests in multiple sclerosis. AMA Arch Neurol Psych 71:405-424
15. Kojima H, Uemura M, Sakurai S, Ann T, Ishii Y, Imazu H, Yoshikawa M, Ichijima K, Fukui H (2002) Clinical features of liver disturbance in rheumatoid diseases: clinicopathological study with special reference to the cause of liver disturbance. J Gastroenterol 37:617-625
16. Thompson P Jr, Strum D, Boehm T, Wartofsky L (1978) Abnormalities of liver function tests in tyrotoxicosis. Mil Med 143:548-551
17. Nunez-Martinez O, Alvarez E, Clemente G, Rodriguez-Mahuo M, de Andres C (2003) Autoimmune hepatitis and multiple sclerosis P161. Mult Scler 9:S34-S35
18. Pontecorvo MJ, Levinson JD, Roth JA (1992) A patient with primary biliary cirrhosis and multiple sclerosis. Am J Med 92:433-436
19. Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN (2002) Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum 46:1851-1856
20. Sadovnick AD, Paty DW (1989) Concurrence of Multiple Sclerosis and Inflammatory bowel disease. N Engl J Med 321:762-763
21. Renton KW (2001) Alterations of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163
22. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der Meche FG, van Doorn PA, Hintzen RQ (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125:952-960
23. nd edn. Elsevier, Amsterdam
24. Tremlett HL, Wiles CM, Luscombe DK (2001) Prescribing for MS patients in General Practice: a case control study. J Clin Pharm Ther 26:437-444
25. Larrey D (2000) Drug-induced liver diseases. J Hepatol 32:77-88
26. Sterling MJ, Kane M, Grace ND (1996) Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 91:2233-2234
27. Chan CH (1990) Dantrolene sodium and hepatic injury. Neurology 40:1427-1432
28. Lapierre Y, Bouchard S, Tansey C, Gendron D, Barkas WJ, Francis GS (1987) Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 14:513-517
29. Schattner A, Von der Walde J, Kozak N, Sokolovskaya N, Knobler H (1999) Nitrofurantoin-induced immune-mediated lung and liver disease. Am J Med Sci 317:336-340
30. Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L (1991) Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 32:715-717
31. Davies DM, Cavanagh J (1967) Jaundice from potassium p-aminobenzoate. Lancet 1:896
32. Luparini R, Rotundo A, Mattace R, Marigliano V (2000) Possibly ranitidine-induced autoimmune hepatitis. Ann Ital Med Int 15:214-217
33. Hullar TE, Sapers BL, Ridker PM, Jenkins RL, Huth TS, Farraye FA (1999) Herbal toxicity and fatal hepatic failure. Am J Med 106:267-268
34. Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK (2003) Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36:133-141
35. Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M (1998) Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 50:570-571
36. Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW, Oger JJ, Hashimoto SA (2001) Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 56:1416
37. Francis GS, Grumser Y, Alteri E, Micaleff A, O'Brien F, Alsop J, Moraga MS, Kaplowitz N (2003) Hepatic Reactions during treatment of Multiple Sclerosis with Interferon-beta-1a. Drug Safety 26:815-827
38. Duchini A (2002) Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 97:767-768
39. Jacobs LD, The Multiple Sclerosis Collaborative Research Group (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
40. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
41. Tremlett H, Yoshida EM, Oger J (2004) Liver injury associated with the Beta-Interferons for MS: a comparison between the three products. Neurology 62:628-631
42. Benichou C, CIOMS (1990) Criteria of drug-induced liver disorders. J Hepatol 11:272-276
43. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
44. Nosaka K, Sakamoto K (1999) Changes in plasma enzyme activity after intramuscular injection of bupivacaine into the human biceps brachii. Acta Physiol Scand 167:259-265
45. Perry MC (1992) Chemotherapeutic agents and heptotoxicity. Sem Oncol 19:551-565
46. Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW (1993) Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplasic syndromes. Am J Clin Oncol 16:159-163
47. Fujimore K, Mochida S, Matsui A, Ohno A, Fujiwara K (2002) Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients. J Gastroenterol 37:40-46
48. Kellokumpu-Lehtinen P, Iisalo E, Nordman E (1989) Hepatotoxicity of paracetamol in combination with interferon and vinblastine. Lancet 1:1143
49. Fabris P, Palma MD, de Lalla F (2001) Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon-alpha. Ann Intern Med 134:345
50. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C (2002) Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 249:50-56
51. Lee WM (2003) Drug-induced Hepatotoxicity. N Engl J Med 349:474-485
52. Sena A, Pedrosa R, Ferret-Sena V, Almeida R, Andrade ML, Morais MG, Couderc R (2000) Interferon betala therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clin Chem Lab Med 38:209-213
53. Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH (1992) The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12:1053-1062
54. Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shrago ES (1987) Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis 67:261-267
55. Amacher DE (1998) Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 27:119-130
56. Anonymous (2003) Common Terminology Criteria for Adverse Events, National Cancer Institute. Cancer Therapy Evaluation Program. http://ctep.cancer.gov/ reporting/ctc.ht ml (Accessed 10 July, 2003)
57. Wang CS, Wang ST, Chang TT, Yao WJ, Chou P (2002) Smoking and Alanine Aminotransferase Levels in Hepatitis C Virus Infection. Arch Intern Med 162:811-815
58. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
59. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M (2001) Liver and thyroid function and auto immunity during interferon-beta 1b treatment for MS. Neurology 57:1363-1370